aetna terminated my approved Entyvio infusions for Crohns disease after 3 years of stable continuous approvals, citing "new step therapy" requirements - but i already failed step therapy on Humira and 6MP at initial diagnosis in 2023. how do i invoke continuation-of-care and non-medical-switching protections to keep my biologic without restarting the protocol from scratch?

looking for community guidance on what feels like a textbook non-medical-switching denial. i have been stable on a biologic for 3 years and the carrier is now trying to force me back through a step-therapy gauntlet i already failed.

background. 38 year old male, diagnosed with moderate-to-severe Crohn's disease in 2023 after about 18 months of escalating symptoms and a delayed diagnosis. initial treatment per my gastroenterologist followed the standard step-therapy protocol: started on mesalamine (5-ASA) which did nothing because my disease is moderate-to-severe and 5-ASA is essentially first-line for mild colitis only. moved to a 6-month course of azathioprine (6-MP) which i could not tolerate due to severe hepatotoxicity (LFTs running 4x upper limit by month 3, had to discontinue). then moved to Humira (adalimumab) per the TNF-inhibitor pathway, which i was on for 10 months with inadequate response (continued active inflammation on scope, elevated fecal calprotectin, ongoing symptoms). at that point my gastroenterologist documented step-therapy failure on TWO biologic classes (immunomodulators and TNF inhibitors) and moved me to Entyvio (vedolizumab), which is the gut-selective integrin antagonist - different mechanism of action, different safety profile.

i have been on Entyvio for 3 years now. INFUSION every 8 weeks, $11,400 per dose at the infusion center, fully covered under my Aetna plan through my employer. i have been in clinical remission for 18 months - calprotectin at normal levels, no active disease on the last 3 scopes, no flares, no hospitalizations. i am living a normal life. my gastroenterologist is delighted because i am one of his stable success stories.

my employer changed insurance carriers at open enrollment last December. moved from Aetna self-insured ASO to Aetna fully-insured (same parent but different plan structure and different pharmacy management). the new plan year started January 2026.

last week i received a letter from Aetna SpecialtyRx informing me that "effective with your next scheduled infusion, your Entyvio therapy will require new prior authorization under the plan's updated specialty pharmacy management program." they are requiring me to "complete step therapy on preferred agents Humira and Stelara before continuing on Entyvio coverage." they referenced the plan's 2026 specialty drug formulary updates as the basis for the requirement.

this is insane. let me list the specific issues:

(1) i already FAILED step therapy on Humira in 2023-2024. it is in my medical record. my gastroenterologist documented the failure with active scope findings, elevated inflammatory markers, and ongoing symptoms. the failure documentation is in the chart that Aetna has full access to. they are telling me to fail the same drug again under a "new" plan year.

(2) i was never on Stelara because Stelara is approved for Crohn's but is not typically used after Humira failure in my clinical scenario. the standard care progression after TNF inhibitor failure in CD is either Entyvio (integrin) or Stelara (IL-12/23 inhibitor) depending on clinical judgment. my gastroenterologist chose Entyvio based on my disease pattern and tolerability profile. forcing me onto Stelara now is not "step therapy", it is non-medical-switching of my established working therapy to satisfy a formulary preference.

(3) interrupting Entyvio specifically is clinically risky. there is documented anti-drug antibody formation risk when you discontinue and restart vedolizumab. patients who lose response after a treatment interruption may not regain response on resumption. my gastroenterologist is adamant that i should not be cycled off the working therapy.

(4) the financial gap during the dispute is brutal. my next infusion is in 4 weeks. if Aetna does not authorize, the specialty pharmacy will not ship the drug, and the infusion center will not infuse without product. my out-of-pocket for one infusion is $11,400 if i pay cash. that is not sustainable. and missing infusions risks losing remission.

(5) i am in a continuation-of-care window under federal and state law. ERISA continuation-of-care provisions, plus my state's (Colorado) explicit Continuity of Care law, plus the carrier's own member-handbook continuity-of-care provisions all provide some level of protection for patients whose established therapy is mid-course at the time of a plan transition.

my gastroenterologist filed an urgent peer-to-peer review request with Aetna last Friday. the Aetna medical director (a Dr. who per linkedin is internal medicine background, no GI training, current role is exclusively Aetna utilization management) declined the appeal and reiterated the step-therapy requirement. my gastroenterologist documented in the chart that the peer-to-peer was "uninformed and procedurally inadequate" and is now drafting a written formal appeal.

questions for the community (this is my first time fighting a denial like this):

(1) the controlling framework - what is the actual legal/regulatory framework that protects against non-medical-switching of established therapy? i have heard references to (a) federal ACA continuation-of-care provisions, (b) state continuity-of-care statutes that vary by state, (c) the EBSA/DOL self-funded plan rules, (d) state Department of Insurance regulations on prior authorization. which of these actually has teeth and where do i invoke them in the appeal?

(2) prior step-therapy failure documentation - is there a standard format or specific language that carriers are required to accept as "documentation of prior step-therapy failure"? my gastroenterologist's office notes from 2023-2024 document the Humira failure clearly but the carrier might argue the documentation is "insufficient" as a pretext. what does adequate documentation look like in the carrier's view?

(3) the urgent appeal process - my next infusion is in 4 weeks. is this an "urgent" appeal that gets expedited review (72 hour turnaround under ACA standards), or is it a "standard" appeal (30-60 day turnaround)? interrupting Entyvio mid-course feels urgent to me but the carrier may classify it as standard.

(4) external review - if internal appeals fail, what is the external review process for this kind of medical-necessity denial? i have heard external review reverses carrier decisions at a high rate for documented medical-necessity cases. is the external review claimant-friendly here?

(5) state DOI complaint - Colorado DOI has a complaint process for prior authorization disputes. is this useful in parallel with the internal appeals, or does it slow things down?

(6) the financial bridge - assuming the appeal takes 6-12 weeks to resolve, how do i avoid missing infusions and losing remission? options i can see: (a) drug manufacturer patient assistance program (Takeda has Entyvio Connect which may bridge), (b) the infusion center may have charity care or extended payment plans, (c) out-of-pocket then claim reimbursement after appeal success, (d) advocate for an expedited interim authorization pending appeal resolution. which is the realistic path?

(7) employer angle - my employer is an ~800 employee company, my HR director has been responsive on prior issues. should i loop HR into this fight? the employer pays the premium and has some leverage with the carrier, but i do not want to be "the difficult employee with the expensive condition." has anyone successfully escalated through employer HR/benefits to force a carrier reversal?

(8) attorney involvement - is this big enough that i should engage a patient-advocacy attorney or a healthcare-coverage attorney now? or is this DIY-able with my gastroenterologist's support letter, the prior records, and the appeals process? what is the actual cost of attorney engagement on a coverage dispute like this if i wanted to involve one?

(9) the bigger picture - this feels like the carrier is using the plan-year transition as a pretext to re-litigate established therapy decisions and push patients onto cheaper formulary preferred drugs (Humira biosimilars are now in the $4k/month range vs Entyvio at $11k). is there an industry pattern here that other CD/UC patients on Entyvio are also seeing? i would love to know if this is happening to others or if i am uniquely targeted.

3 years of stable remission and the carrier wants to disrupt it for a formulary preference. this is exactly the kind of "non-medical switching" that patient advocacy organizations have been warning about. i am not letting them roll me but i need to make sure i am running the right plays.

thanks all for any guidance. happy to update once this resolves.